EFM
OVID icon

E Fund Management’s Ovid Therapeutics OVID Stock Holding History

E Fund Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9K Buy
+19,286
New +$49.8K ﹤0.01% 486

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

E Fund Management's OVID Position: Q2 2026 in Review

E Fund Management opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 19,286 shares worth $51.9K. The stake represents ﹤0.01% of the portfolio and ranks #486 among its holdings.

131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • E Fund Management held 19,286 shares of Ovid Therapeutics worth $51.9K as of Q2 2026.
  • Ovid Therapeutics was a new E Fund Management position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #486 holding.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.